The expression of MAGE genes according to pathological stages in bladder and upper tract urothelial cancersa,b
| Pathological stage | No. of tumors | No. of MAGE + tumors | ||||||
|---|---|---|---|---|---|---|---|---|
| MAGE-1 | MAGE-2 | MAGE-3 | Any of three | |||||
| Bladder cancer | ||||||||
| <pT1 | 17 | 1 | 1 | 1 | 1 (6%) | |||
| pT2≤ | 11 | 4 | 3 | 6 | 8 (73%)c | |||
| Total | 28 | 5 | 4 | 7 | 9 (32%) | |||
| Upper tract urothelial cancer | ||||||||
| <pT1 | 4 | 2 | 1 | 1 | 2 (50%) | |||
| pT2≤ | 4 | 3 | 4 | 4 | 4 (100%) | |||
| Total | 8 | 5 | 5 | 5 | 6 (75%) | |||
a Clinical tissue samples were obtained from the patients at the time of surgery performed at Keio University Hospital.
b Expression of MAGE genes was detected by RT-PCR amplification of total RNA isolated from each sample using specific oligonucleotide primers.
c Statistical significance between stages <pT1 and pT2≤ was analyzed by Mann-Whitney nonparametric U test. P = 0.0003.